Serum Free Light Chains
- Also Known As:
- Free Light Chains
- SFLC
- FLC
- Kappa and Lambda Free Light Chains
- Quantitative Serum Free Light Chains with Ratio
- Formal Name:
- Light Chains
- Free|Free Kappa/Lambda Ratio

This page was fact checked by our expert Medical Review Board for accuracy and objectivity. Read more about our editorial policy and review process.
.At a Glance
Why Get Tested?
To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment
When To Get Tested?
When you have bone pain, fractures, anemia (with normal size and shape red blood cells (normocytic)), kidney disease, and recurrent infections that your health care practitioner suspects are due to a plasma cell disorder; when you are being treated for a plasma cell disorder
Sample Required?
A blood sample drawn from a vein in your arm
Test Preparation Needed?
None
What is being tested?
Light chains are proteins produced by immune cells called plasma cells. Also called kappa and lambda light chains, they link together with other proteins (heavy chains) to form immunoglobulins (also known as antibodies) that target and neutralize specific threats to the body such as bacteria and viruses. Plasma cells normally produce some excess light chains that do not combine with heavy chains and instead enter the bloodstream. Free light chains (FLC) or serum free light chains (SFLC) refer to those that are not part of whole (intact) immunoglobulins and are present in the blood. This test measures the amount of free kappa and lambda light chains in the blood and calculates a kappa/lambda ratio to help detect, diagnose, and monitor conditions associated with an increased production of free light chains.
Each type of immunoglobulin is composed of four protein chains: two identical heavy chains and two identical light chains. A particular plasma cell will produce only one type of immunoglobulin. Normally, there is a slight excess of free light chains produced, so low levels of free kappa and lambda chains are detected in the blood.
With a group of conditions called plasma cell disorders (dyscrasias) or monoclonal gammopathies, a plasma cell becomes neoplastic, dividing more than it should and producing a large number of copies (clones) of itself that crowd out other cells in the bone marrow. Since the clones come from a single plasma cell, they may produce large amounts of the same type of abnormal monoclonal immunoglobulin (M-protein). This may be an intact immunoglobulin, only a light chain, or rarely only a heavy chain.
Excess light chain production may be seen with any of the plasma cell disorders, such as multiple myeloma, MGUS (monoclonal gammopathy of unknown significance, a condition that may progress to multiple myeloma), monoclonal light chain (primary) amyloidosis, and others. These conditions may go unnoticed or may progress to produce various signs and symptoms characteristic of the different diseases.
Common Questions
View Sources
Sources Used in Current Review
2017 review performed by Gregary T. Bocsi, DO.
Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. Available online at https://www.ncbi.nlm.nih.gov/pubmed/25439696. Accessed May 2017.
Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-46. Available online at https://www.ncbi.nlm.nih.gov/pubmed/27511158. Accessed May 2017.
Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol. 2014 Dec;89(12):1132-40. Available online at https://www.ncbi.nlm.nih.gov/pubmed/25407896. Accessed May 2017.
Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418-23. Available online at http://meetinglibrary.asco.org/content/159009-176. Accessed May 2017.
Bridoux F, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015 Apr;87(4):698-711. Available online at https://www.ncbi.nlm.nih.gov/pubmed/25607108. Accessed May 2017.
Yadav P, et al. The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease. Kidney Int. 2015 Apr;87(4):692-7. Available online at https://www.ncbi.nlm.nih.gov/pubmed/25296094. Accessed May 2017.
Sources Used in Previous Reviews
Rogoski, R. (2009 July). Serum free light chain assays: Detecting plasma cell disorders. Medical Laboratory Observer [On-line information]. Available online at http://www.mlo-online.com/features/2009_july/0709_coverstory.aspx. Accessed August 2010.
(© 1995–2010). Unit Code 84190: Immunoglobulin Free Light Chains, Serum. Mayo Clinic, Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/84190. Accessed August 2010.
Delgado, J. et. al. (Updated 2010 August). Plasma Cell Dyscrasias. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/PlasmaCellDyscrasias.html?client_ID=LTD#tabs=0. Accessed August 2010.
Grethlein, S. and Thomas, L. (Updated 2010 June 28). Multiple Myeloma. eMedicine. [On-line information]. Available online at http://emedicine.medscape.com/article/204369-overview. Accessed August 2010.
Hutchison, C. et. al. (2008 November 5). Serum Free Light Chain Measurement Aids the Diagnosis of Myeloma in Patients With Severe Renal Failure. Medscape from BMC Nephrology [On-line information]. Available online at http://www.medscape.com/viewarticle/582826. Accessed August 2010.
Faix, J. (2009 March/April). Serum Free Light Chain for Monoclonal Immunoglobulin Detection and Management. Stanford Hospital and Clinics, LABletter [On-line information]. PDF available for download at http://www.stanfordlab.com/images/PDF/2009MarApr.pdf. Accessed August 2010.
Nau, K. and Lewis, W. (2008 October 1). Multiple Myeloma. Am Fam Physician. 2008 Oct 1;78(7): 853-859 [On-line information]. Available online at http://www.aafp.org/afp/2008/1001/p853.html. Accessed August 2010.
Hutchison, C. et. al. (2009 November). Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nature Reviews Nephrology 5, 621-628 [On-line information]. Available online at http://www.nature.com/nrneph/journal/v5/n11/full/nrneph.2009.151.html. Accessed August 2010.
Killingsworth, L. (2009 January). Free Light Chain Assays, Enhanced Tools for the Diagnosis and Monitoring of Monoclonal Gammopathies. PAML Test Update [On-line information]. PDF available for download at http://www.paml.com/Files/TestUpdates/38270747_TestUpdateFreeLightChainAssays.pdf. Accessed August 2010.
Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 203.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 674-675.
Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2009) 23, 215–224. Available onlien at http://www.nature.com/leu/journal/v23/n2/full/leu2008307a.html. Accessed September 2010.
MayoClinic.com. Amyloidosis. Available online at http://www.mayoclinic.com/health/amyloidosis/DS00431. Accessed September 2010.
(October 5, 2005) Amyloidosis Foundation. What is amyloidosis? Available online at http://amyloidosis.org/whatisit.asp. Accessed September 2010.
(January 2010) Cancer.net. Amyloidosis. Available online at http://www.cancer.net/patient/Cancer+Types/Amyloidosis?sectionTitle=Symptoms. Accessed September 2010.
Tosi, P. et. al. (2013). Serum Free Light-chain Assay for the Detection and Monitoring of Multiple Myeloma and Related Conditions. Medscape Multispecialty from Ther Adv Hem. 2013;4(1):37-41. [On-line information]. Available online at http://www.medscape.com/viewarticle/779242. Accessed December 2013.
Charafeddine, K. et. al. (2012). Extended Use of Serum Free Light Chain as a Biomarker in Lymphoproliferative Disorders. Medscape Multispecialty from Am J Clin Pathol. 2012;137(6):890-897. [On-line information]. Available online at http://www.medscape.com/viewarticle/765905. Accessed December 2013.
Parmar, M. (Updated 2013 April 18). Light Chain-Associated Renal Disorders. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/244082-overview. Accessed December 2013.
Bahler, D. et. al. (Updated 2013 June). Plasma Cell Dyscrasias. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/PlasmaCellDyscrasias.html?client_ID=LTD#tabs=0. Accessed December 2013.
(© 1995–2013). Immunoglobulin Free Light Chains, Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/84190. Accessed December 2013.
Boppana, S. and Sacher, R. (Updated 2013 April 29). Light-Chain Deposition Disease. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/202585-overview. Accessed December 2013
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby’s Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 150-151.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 243-244.
Ask a Laboratory Scientist
